Meanwhile, the acquisition of AntlerA, which Roche called a leader in Wnt signaling, gives the pharma ownership of a library ...

Roche RHHBY announced an asset purchase agreement with clinical-stage biotechnology company Regor Therapeutics. Per the ...

Genentech’s parent company Roche said the $850m deal lines up with its plan to focus on three therapeutic areas including ...

The Swiss pharma is paying Regor Therapeutics $850 million to buy a pair of prospects it sees as potential successors to blockbuster medicines from Pfizer and Eli Lilly.

Genentech has acquired Regor Pharmaceuticals’ next-generation CDK inhibitors for breast cancer treatment in a deal worth ...

Roche is spending $850 million upfront to buy Regor Pharmaceuticals’ suite of next-generation CDK inhibitors as it doubles ...

Roche focuses on obesity drug development, fast-tracking its CT-388 candidate, and targeting $3.6 billion in annual sales.

Sino-American biotech Regor Pharmaceuticals has entered into a definitive purchase agreement whereby Swiss pharma major Roche ...

Regor Pharmaceuticals USA has entered into a definitive purchase agreement, under which Genentech, a member of the Roche Group, will ...

Dow Jones Newswires is a market-moving financial and business news source, used by wealth managers, institutional investors and fintech platforms around the world to identify trading and investing ...

Further, Roche announced asset purchase with Regor Therapeutics to acquire its next-generation CDK inhibitor portfolio in breast cancer. In Switzerland, Roche shares were trading at 271.10 Swiss ...

Cambridge, Massachusetts-based biotech Regor Therapeutics Group has agreed to sell its portfolio of CDK inhibitors for the ...